Industries > Pharma > Alzheimer’s Drugs Market Report to 2031
Alzheimer’s Drugs Market Report to 2031
Forecasts by Drugs (Donepezil, Rivastigmine, Galantamine, and Memantine), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and e-Commerce) PLUS COVID-19 Recovery Scenarios
Alzheimer’s Drugs Market – our new study reveals trends, R&D progress, and predicted revenues
Where the Alzheimer’s is Drugs market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2031, assessing data, trends, opportunities and business prospects there.
Discover how to stay ahead
Our 500+ page report provides 600+ tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Alzheimer’s Drugs Market. See how to exploit the opportunities.
Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.
Discover sales predictions for the world market and submarkets
Alzheimer’s Drugs Market: By Drugs
• Donepezil
• Rivastigmine
• Galantamine
• Memantine
Alzheimer’s Drugs Market: By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• e-Commerce
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 20 leading national markets:
• North America
o U.S.
o Canada
• Europe
o Germany
o France
o United Kingdom
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o Australia
o South Korea
o Rest of Asia Pacific
• Latin America
o Brazil
o Mexico
o Argentina
o Rest of Latin America
• Middle East and Africa
o Turkey
o Saudi Arabia
o South Africa
o UAE
o Egypt
o Rest of Middle East and Africa
The report also includes profiles and for some of the leading companies in the Alzheimer’s Drugs Market, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
Overall world revenue for Alzheimer’s Drugs Market will surpass $xx million in 2021, our work calculates. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Alzheimer’s Drugs Market report helps you
In summary, our 500+ page report provides you with the following knowledge:
• Revenue forecasts to 2031 for Alzheimer’s Drugs Market, with forecasts for Drug Type and Distribution Channel, each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2031 for 5 regional and 16 key national markets – See forecasts for the Alzheimer’s Drugs market in North America, Europe, Asia-Pacific and Rest of the World. Also forecasted is the market in the US, Canada, Argentina, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for 10 of the major companies involved in the Alzheimer’s Drugs Market. Some of the company’s profiled in this report include Pfizer, Inc., Janssen Pharmaceutical, Novartis International AG, Eisai Co. Ltd., Lundbeck A/S and Teva Pharmaceuticals Industries Ltd., Other prominent players whose products are under clinical trials are Eli Lilly and Company, TauRx Pharmaceuticals Ltd, VTV Therapeutics, Hoffman-La Roche Ltd., AstraZeneca plc, and AC Immune.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Alzheimer’s Drugs Market Report to 2031: Forecasts by Drugs (Donepezil, Rivastigmine, Galantamine, and Memantine), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and e-Commerce) PLUS COVID-19 Recovery Scenarios. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered by This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Alzheimer’s Drugs Market
2.1. Alzheimer’s Drugs Market Definition
2.2. Drugs Submarkets Definitions
2.3. Distribution Channel Submarkets Definitions
3. Alzheimer’s Drugs Market Overview
3.1. Global Alzheimer’s Drugs Market Size and Forecast by Region
3.2. Global Alzheimer’s Drugs Market Share by Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Growing occurrence of diseases in developed western countries
3.3.1.2. Steady government support for Alzheimer's drug development, growing awareness about treatment of Alzheimer's disease
3.3.2. Market Restraints/Challenges
3.3.2.1. High prices of advanced drugs
3.3.2.2. Awareness about Alzheimer's disease remains limited in developing countries like Southeast Asia
3.3.3. Opportunities
3.3.3.1. Growing support for mental care infrastructure from governments in several developing Asia Pacific countries is thus likely to drive the Alzheimer's drugs market in the region in the coming years
3.3.4. Global Alzheimer’s Drugs Market: Trends
3.3.5. SWOT Analysis
3.3.5.1. Strengths
3.3.5.2. Weaknesses
3.3.5.3. Opportunities
3.3.5.4. Threats
3.3.6. Porter’s Five Forces Analysis
3.3.6.1. Competitive Rivalry
3.3.6.2. Supplier Power
3.3.6.3. Buyer Power
3.3.6.4. Threat of Substitution
3.3.6.5. The threat of New Entry
4. Global Alzheimer’s Drugs Market Analysis and Forecast, 2021-2031 by Drugs (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. Donepezil
4.1.2. Rivastigmine
4.1.3. Galantamine
4.1.4. Memantine
5. Global Alzheimer’s Drugs Market Analysis and Forecast, 2021-2031 by Distribution Channel (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Hospital Pharmacy
5.1.2. Retail Pharmacy
5.1.3. E-Commerce
6. North America Alzheimer’s Drugs Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
6.1. Market Overview
6.2. North America Alzheimer’s Drugs Market Size and Forecast by Drugs
6.3. North America Alzheimer’s Drugs Market Size and Forecast by Distribution Channel
6.4. U.S. Alzheimer’s Drugs Market
6.5. Canada Alzheimer’s Drugs Market
7. Europe Alzheimer’s Drugs Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
7.1. Market Overview
7.2. Europe Alzheimer’s Drugs Market Size and Forecast by Drugs
7.3. Europe Alzheimer’s Drugs Market Size and Forecast by Distribution Channel
7.4. UK Alzheimer’s Drugs Market
7.5. Germany Alzheimer’s Drugs Market
7.6. France Alzheimer’s Drugs Market
7.7. Rest of Europe Alzheimer’s Drugs Market
8. Asia Pacific Alzheimer’s Drugs Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
8.1. Market Overview
8.2. Asia Pacific Alzheimer’s Drugs Market Size and Forecast by Drugs
8.3. Asia Pacific Alzheimer’s Drugs Market Size and Forecast by Distribution Channel
8.4. China Alzheimer’s Drugs Market
8.5. India Alzheimer’s Drugs Market
8.6. Japan Alzheimer’s Drugs Market
8.7. Rest of Asia Pacific Alzheimer’s Drugs Market
9. Latin America Alzheimer’s Drugs Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
9.1. Market Overview
9.2. Latin America Alzheimer’s Drugs Market Size and Forecast by Drugs
9.3. Latin America Alzheimer’s Drugs Market Size and Forecast by Distribution Channel
9.3.1. Brazil Alzheimer’s Drugs Market
9.3.2. Mexico Alzheimer’s Drugs Market
9.3.3. Rest of Latin America Alzheimer’s Drugs Market
10. MEA Alzheimer’s Drugs Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. MEA Alzheimer’s Drugs Market Size and Forecast by Drugs
10.3. MEA Alzheimer’s Drugs Market Size and Forecast by Distribution Channel
10.4. GCC Alzheimer’s Drugs Market
10.5. South Africa Alzheimer’s Drugs Market
10.6. Rest of MEA Alzheimer’s Drugs Market
11. Companies in the Alzheimer’s Drugs Market
11.1. Pfizer, Inc.
11.1.1. Company Snapshot
11.1.2. Company Overview
11.1.3. Financial Performance (2015-2019)
11.1.3.1. Net Revenue
11.1.3.2. Gross Profit
11.1.3.3. Geographical Revenue, 2019
11.1.4. Product Offerings
11.1.5. Recent Initiatives (2017-2019)
11.2. Janssen Pharmaceutical
11.2.1. Company Snapshot
11.2.2. Company Overview
11.2.3. Financial Performance (2015-2019)
11.2.3.1. Net Revenue
11.2.3.2. Gross Profit
11.2.3.3. Geographical Revenue, 2019
11.2.4. Product Offerings
11.2.5. Recent Initiatives (2017-2019)
11.3. Novartis International AG
11.3.1. Company Snapshot
11.3.2. Company Overview
11.3.3. Financial Performance (2015-2019)
11.3.3.1. Net Revenue
11.3.3.2. Gross Profit
11.3.3.3. Geographical Revenue, 2019
11.3.4. Product Offerings
11.3.5. Recent Initiatives (2017-2019)
11.4. Eisai Co. Ltd.
11.4.1. Company Snapshot
11.4.2. Company Overview
11.4.3. Financial Performance (2015-2019)
11.4.3.1. Net Revenue
11.4.3.2. Gross Profit
11.4.3.3. Geographical Revenue, 2019
11.4.4. Product Offerings
11.4.5. Recent Initiatives (2017-2019)
11.5. Lundbeck A/S
11.5.1. Company Snapshot
11.5.2. Company Overview
11.5.3. Financial Performance (2015-2019)
11.5.3.1. Net Revenue
11.5.3.2. Gross Profit
11.5.3.3. Geographical Revenue, 2019
11.5.4. Product Offerings
11.5.5. Recent Initiatives (2017-2019)
11.6. Teva Pharmaceuticals Industries Ltd.
11.6.1. Company Snapshot
11.6.2. Company Overview
11.6.3. Financial Performance (2015-2019)
11.6.3.1. Net Revenue
11.6.3.2. Gross Profit
11.6.3.3. Geographical Revenue, 2019
11.6.4. Product Offerings
11.6.5. Recent Initiatives (2017-2019)
11.7. Eli Lilly and Company
11.7.1. Company Snapshot
11.7.2. Company Overview
11.7.3. Financial Performance (2015-2019)
11.7.3.1. Net Revenue
11.7.3.2. Gross Profit
11.7.3.3. Geographical Revenue, 2019
11.7.4. Product Offerings
11.7.5. Recent Initiatives (2017-2019)
11.8. TauRx Pharmaceuticals Ltd
11.8.1. Company Snapshot
11.8.2. Company Overview
11.8.3. Financial Performance (2015-2019)
11.8.3.1. Net Revenue
11.8.3.2. Gross Profit
11.8.3.3. Geographical Revenue, 2019
11.8.4. Product Offerings
11.8.5. Recent Initiatives (2017-2019)
11.9. VTV THERAPEUTICS
11.9.1. Company Snapshot
11.9.2. Company Overview
11.9.3. Financial Performance (2015-2019)
11.9.3.1. Net Revenue
11.9.3.2. Gross Profit
11.9.3.3. Geographical Revenue, 2019
11.9.4. Product Offerings
11.9.5. Recent Initiatives (2017-2019)
11.10. Hoffman-La Roche Ltd.
11.10.1. Company Snapshot
11.10.2. Company Overview
11.10.3. Financial Performance (2015-2019)
11.10.3.1. Net Revenue
11.10.3.2. Gross Profit
11.10.3.3. Geographical Revenue, 2019
11.10.4. Product Offerings
11.10.5. Recent Initiatives (2017-2019)
11.11. Other Notable Players
12. Conclusion
13. Glossary
Associated Visiongain Reports
Visiongain Report Sales Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1 Alzheimer’s Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2 Alzheimer’s Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3 Alzheimer’s Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4 Alzheimer’s Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5 Alzheimer’s Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6 Alzheimer’s Drugs Market Drivers & Restraints 2020
Table 7 Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 8 Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 9 Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 10 Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 11 Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 12 Donepezil Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13 Donepezil Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14 Donepezil Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15 Donepezil Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16 Donepezil Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17 Rivastigmine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 18 Rivastigmine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 19 Rivastigmine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 20 Rivastigmine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 21 Galantamine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 22 Galantamine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 23 Galantamine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 24 Galantamine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 25 Galantamine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 26 Memantine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 27 Memantine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 28 Memantine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 29 Memantine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 30 Memantine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 31 Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 32 Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 33 Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 34 Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 35 Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 36 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 37 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 38 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 39 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 40 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 41 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 42 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 43 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 44 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 45 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 46 E-Commerce Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 47 E-Commerce Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 48 E-Commerce Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 49 E-Commerce Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 50 E-Commerce Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 51 Regional Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 52 Regional Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 53 Regional Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 54 Regional Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 55 Regional Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 56 North America Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 57 North America Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 58 North America Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 59 North America Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 60 North America Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 61 North America Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 62 North America Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 63 North America Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 64 North America Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 65 North America Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 66 North America Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 67 North America Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 68 North America Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 69 North America Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 70 North America Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 71 US Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 72 US Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 73 US Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 74 US Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 75 US Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 76 Canada Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 77 Canada Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 78 Canada Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 79 Canada Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 80 Canada Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 81 Europe Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 82 Europe Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 83 Europe Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 84 Europe Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 85 Europe Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 86 Europe Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 87 Europe Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 88 Europe Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 89 Europe Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 90 Europe Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 91 Europe Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 92 Europe Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 93 Europe Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 94 Europe Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 95 Europe Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 96 UK Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 97 UK Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 98 UK Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 99 UK Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 100 UK Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 101 Germany Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 102 Germany Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 103 Germany Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 104 Germany Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 105 Germany Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 106 France Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 107 France Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 108 France Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 109 France Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 110 France Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 111 Rest of Europe Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 112 Rest of Europe Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 113 Rest of Europe Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 114 Rest of Europe Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 115 Rest of Europe Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 116 Asia Pacific Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 117 Asia Pacific Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 118 Asia Pacific Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 119 Asia Pacific Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 120 Asia Pacific Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 121 Asia Pacific Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 122 Asia Pacific Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 123 Asia Pacific Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 124 Asia Pacific Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 125 Asia Pacific Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 126 Asia Pacific Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 127 Asia Pacific Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 128 Asia Pacific Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 129 Asia Pacific Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 130 Asia Pacific Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 131 China Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 132 China Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 133 China Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 134 China Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 135 China Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 136 India Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 137 India Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 138 India Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 139 India Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 140 India Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 141 Japan Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 142 Japan Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 143 Japan Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 144 Japan Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 145 Japan Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 146 RoAPAC Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 147 RoAPAC Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 148 RoAPAC Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 149 RoAPAC Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 150 RoAPAC Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 151 Middle East Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 152 Middle East Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 153 Middle East Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 154 Middle East Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 155 Middle East Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 156 Middle East Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 157 Middle East Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 158 Middle East Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 159 Middle East Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 160 Middle East Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 161 Latin America Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 162 Latin America Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 163 Latin America Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 164 Latin America Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 165 Latin America Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 166 Latin America Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 167 Latin America Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 168 Latin America Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 169 Latin America Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 170 Latin America Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 171 Africa Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 172 Africa Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 173 Africa Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 174 Africa Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 175 Africa Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 176 Africa Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 177 Africa Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 178 Africa Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 179 Africa Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 180 Africa Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 181 Leading 10 Alzheimer’s Drugs Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 182 Pfizer, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 183 Pfizer, Inc. Alzheimer’s Drugs Selected Recent Contracts 2019 (Date, Contract Treatment Type, Details)
Table 184 Pfizer, Inc. Alzheimer’s Drugs Product Offering (Segment, Product Offerings)
Table 185 Janssen Pharmaceutical Profile 2019 (CEO, HQ, Founded, Website)
Table 186 Janssen Pharmaceutical Alzheimer’s Drugs Selected Recent Contracts 2019 (Date, Contract Treatment Type, Details)
Table 187 Janssen Pharmaceutical Alzheimer’s Drugs Product Offering (Segment, Product Offerings)
Table 188 Novartis International AG Profile 2019 (CEO, HQ, Founded, Website)
Table 189 Novartis International AG Alzheimer’s Drugs Selected Recent Contracts 2017-2019 (Date, Contract Treatment Type, Details)
Table 190 Novartis International AG Alzheimer’s Drugs Product Offering (Segment, Product Offerings)
Table 191 Eisai Co. Ltd. Profile 2019 (CEO, HQ, Founded, Website)
Table 192 Eisai Co. Ltd. Alzheimer’s Drugs Selected Recent Contracts 2015-2019 (Date, Contract Treatment Type, Details)
Table 193 Eisai Co. Ltd. Alzheimer’s Drugs Product Offering (Segment, Product Offerings)
Table 194 Lundbeck A/S Profile 2019 (CEO, HQ, Founded, Website)
Table 195 Lundbeck A/S Alzheimer’s Drugs Selected Recent Contracts 2015-2019 (Date, Contract Treatment Type, Details)
Table 196 Lundbeck A/S Alzheimer’s Drugs Product Offering (Segment, Product Offerings)
Table 197 Teva Pharmaceuticals Industries Ltd. Profile 2019 (CEO, HQ, Founded, Website)
Table 198 Teva Pharmaceuticals Industries Ltd. Alzheimer’s Drugs Selected Recent Contracts 2015-2019 (Date, Contract Treatment Type, Details)
Table 199 Teva Pharmaceuticals Industries Ltd. Alzheimer’s Drugs Product Offering (Segment, Product Offerings)
Table 200 Eli Lilly and Company Profile 2019 (CEO, HQ, Founded, Website)
Table 201 Eli Lilly and Company Alzheimer’s Drugs Selected Recent Contracts 2015-2019 (Date, Contract Treatment Type, Details)
Table 202 Eli Lilly and Company Alzheimer’s Drugs Product Offering (Segment, Product Offerings)
Table 203 TauRx Pharmaceuticals Ltd Profile 2019 (CEO, HQ, Founded, Website)
Table 204 TauRx Pharmaceuticals Ltd Alzheimer’s Drugs Selected Recent Contracts 2015-2019 (Date, Contract Treatment Type, Details)
Table 205 TauRx Pharmaceuticals Ltd Alzheimer’s Drugs Product Offering (Segment, Product Offerings)
Table 206 VTV THERAPEUTICS Profile 2019 (CEO, HQ, Founded, Website)
Table 207 VTV THERAPEUTICS Alzheimer’s Drugs Selected Recent Contracts 2015-2019 (Date, Contract Treatment Type, Details)
Table 208 VTV THERAPEUTICS Alzheimer’s Drugs Product Offering (Segment, Product Offerings)
Table 209 Hoffman-La Roche Ltd. Profile 2019 (CEO, HQ, Founded, Website)
Table 210 Hoffman-La Roche Ltd. Alzheimer’s Drugs Selected Recent Contracts 2015-2019 (Date, Contract Treatment Type, Details)
Table 211 Hoffman-La Roche Ltd. Alzheimer’s Drugs Product Offering (Segment, Product Offerings)
Table 212 Other Companies Involved in the Alzheimer’s Drugs Market 2020 (Company, Location)
LIST OF FIGURES
Figure 1 Alzheimer’s Drugs Market By Drugs Overview
Figure 2 Alzheimer’s Drugs Market By Distribution Channel Overview
Figure 3 Alzheimer’s Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 4 Alzheimer’s Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 5 Alzheimer’s Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 6 Alzheimer’s Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 7 Alzheimer’s Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 8 Alzheimer’s Drugs Market Drivers & Restraints 2020
Figure 9 Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 10 Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 11 Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 12 Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 13 Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 14 Donepezil Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 15 Donepezil Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 16 Donepezil Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 17 Donepezil Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 18 Donepezil Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 19 Rivastigmine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 20 Rivastigmine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 21 Rivastigmine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 22 Rivastigmine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 23 Galantamine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 24 Galantamine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 25 Galantamine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 26 Galantamine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 27 Galantamine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 28 Memantine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 29 Memantine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 30 Memantine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 31 Memantine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 32 Memantine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 33 Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 34 Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 35 Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 36 Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 37 Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 38 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 39 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 40 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 41 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 42 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 43 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 44 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 45 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 46 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 47 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 48 E-Commerce Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 49 E-Commerce Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 50 E-Commerce Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 51 E-Commerce Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 52 E-Commerce Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 53 Regional Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 54 Regional Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 55 Regional Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 56 Regional Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 57 Regional Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 58 North America Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 59 North America Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 60 North America Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 61 North America Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 62 North America Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 63 North America Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 64 North America Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 65 North America Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 66 North America Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 67 North America Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 68 North America Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 69 North America Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 70 North America Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 71 North America Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 72 North America Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 73 US Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 74 US Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 75 US Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 76 US Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 77 US Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 78 Canada Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 79 Canada Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 80 Canada Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 81 Canada Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 82 Canada Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 83 Europe Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 84 Europe Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 85 Europe Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 86 Europe Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 87 Europe Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 88 Europe Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 89 Europe Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 90 Europe Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 91 Europe Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 92 Europe Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 93 Europe Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 94 Europe Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 95 Europe Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 96 Europe Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 97 Europe Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 98 UK Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 99 UK Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 100 UK Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 101 UK Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 102 UK Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 103 Germany Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 104 Germany Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 105 Germany Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 106 Germany Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 107 Germany Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 108 France Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 109 France Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 110 France Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 111 France Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 112 France Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 113 Rest of Europe Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 114 Rest of Europe Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 115 Rest of Europe Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 116 Rest of Europe Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 117 Rest of Europe Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 118 Asia Pacific Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 119 Asia Pacific Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 120 Asia Pacific Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 121 Asia Pacific Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 122 Asia Pacific Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 123 Asia Pacific Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 124 Asia Pacific Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 125 Asia Pacific Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 126 Asia Pacific Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 127 Asia Pacific Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 128 Asia Pacific Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 129 Asia Pacific Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 130 Asia Pacific Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 131 Asia Pacific Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 132 Asia Pacific Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 133 China Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 134 China Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 135 China Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 136 China Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 137 China Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 138 India Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 139 India Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 140 India Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 141 India Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 142 India Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 143 Japan Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 144 Japan Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 145 Japan Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 146 Japan Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 147 Japan Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 148 RoAPAC Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 149 RoAPAC Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 150 RoAPAC Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 151 RoAPAC Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 152 RoAPAC Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 153 Middle East Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 154 Middle East Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 155 Middle East Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 156 Middle East Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 157 Middle East Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 158 Middle East Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 159 Middle East Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 160 Middle East Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 161 Middle East Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 162 Middle East Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 163 Latin America Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 164 Latin America Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 165 Latin America Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 166 Latin America Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 167 Latin America Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 168 Latin America Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 169 Latin America Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 170 Latin America Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 171 Latin America Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 172 Latin America Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 173 Africa Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 174 Africa Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 175 Africa Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 176 Africa Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 177 Africa Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 178 Africa Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 179 Africa Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 180 Africa Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 181 Africa Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 182 Africa Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered by This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Alzheimer’s Drugs Market
2.1. Alzheimer’s Drugs Market Definition
2.2. Drugs Submarkets Definitions
2.3. Distribution Channel Submarkets Definitions
3. Alzheimer’s Drugs Market Overview
3.1. Global Alzheimer’s Drugs Market Size and Forecast by Region
3.2. Global Alzheimer’s Drugs Market Share by Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Growing occurrence of diseases in developed western countries
3.3.1.2. Steady government support for Alzheimer's drug development, growing awareness about treatment of Alzheimer's disease
3.3.2. Market Restraints/Challenges
3.3.2.1. High prices of advanced drugs
3.3.2.2. Awareness about Alzheimer's disease remains limited in developing countries like Southeast Asia
3.3.3. Opportunities
3.3.3.1. Growing support for mental care infrastructure from governments in several developing Asia Pacific countries is thus likely to drive the Alzheimer's drugs market in the region in the coming years
3.3.4. Global Alzheimer’s Drugs Market: Trends
3.3.5. SWOT Analysis
3.3.5.1. Strengths
3.3.5.2. Weaknesses
3.3.5.3. Opportunities
3.3.5.4. Threats
3.3.6. Porter’s Five Forces Analysis
3.3.6.1. Competitive Rivalry
3.3.6.2. Supplier Power
3.3.6.3. Buyer Power
3.3.6.4. Threat of Substitution
3.3.6.5. The threat of New Entry
4. Global Alzheimer’s Drugs Market Analysis and Forecast, 2021-2031 by Drugs (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. Donepezil
4.1.2. Rivastigmine
4.1.3. Galantamine
4.1.4. Memantine
5. Global Alzheimer’s Drugs Market Analysis and Forecast, 2021-2031 by Distribution Channel (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Hospital Pharmacy
5.1.2. Retail Pharmacy
5.1.3. E-Commerce
6. North America Alzheimer’s Drugs Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
6.1. Market Overview
6.2. North America Alzheimer’s Drugs Market Size and Forecast by Drugs
6.3. North America Alzheimer’s Drugs Market Size and Forecast by Distribution Channel
6.4. U.S. Alzheimer’s Drugs Market
6.5. Canada Alzheimer’s Drugs Market
7. Europe Alzheimer’s Drugs Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
7.1. Market Overview
7.2. Europe Alzheimer’s Drugs Market Size and Forecast by Drugs
7.3. Europe Alzheimer’s Drugs Market Size and Forecast by Distribution Channel
7.4. UK Alzheimer’s Drugs Market
7.5. Germany Alzheimer’s Drugs Market
7.6. France Alzheimer’s Drugs Market
7.7. Rest of Europe Alzheimer’s Drugs Market
8. Asia Pacific Alzheimer’s Drugs Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
8.1. Market Overview
8.2. Asia Pacific Alzheimer’s Drugs Market Size and Forecast by Drugs
8.3. Asia Pacific Alzheimer’s Drugs Market Size and Forecast by Distribution Channel
8.4. China Alzheimer’s Drugs Market
8.5. India Alzheimer’s Drugs Market
8.6. Japan Alzheimer’s Drugs Market
8.7. Rest of Asia Pacific Alzheimer’s Drugs Market
9. Latin America Alzheimer’s Drugs Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
9.1. Market Overview
9.2. Latin America Alzheimer’s Drugs Market Size and Forecast by Drugs
9.3. Latin America Alzheimer’s Drugs Market Size and Forecast by Distribution Channel
9.3.1. Brazil Alzheimer’s Drugs Market
9.3.2. Mexico Alzheimer’s Drugs Market
9.3.3. Rest of Latin America Alzheimer’s Drugs Market
10. MEA Alzheimer’s Drugs Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. MEA Alzheimer’s Drugs Market Size and Forecast by Drugs
10.3. MEA Alzheimer’s Drugs Market Size and Forecast by Distribution Channel
10.4. GCC Alzheimer’s Drugs Market
10.5. South Africa Alzheimer’s Drugs Market
10.6. Rest of MEA Alzheimer’s Drugs Market
11. Companies in the Alzheimer’s Drugs Market
11.1. Pfizer, Inc.
11.1.1. Company Snapshot
11.1.2. Company Overview
11.1.3. Financial Performance (2015-2019)
11.1.3.1. Net Revenue
11.1.3.2. Gross Profit
11.1.3.3. Geographical Revenue, 2019
11.1.4. Product Offerings
11.1.5. Recent Initiatives (2017-2019)
11.2. Janssen Pharmaceutical
11.2.1. Company Snapshot
11.2.2. Company Overview
11.2.3. Financial Performance (2015-2019)
11.2.3.1. Net Revenue
11.2.3.2. Gross Profit
11.2.3.3. Geographical Revenue, 2019
11.2.4. Product Offerings
11.2.5. Recent Initiatives (2017-2019)
11.3. Novartis International AG
11.3.1. Company Snapshot
11.3.2. Company Overview
11.3.3. Financial Performance (2015-2019)
11.3.3.1. Net Revenue
11.3.3.2. Gross Profit
11.3.3.3. Geographical Revenue, 2019
11.3.4. Product Offerings
11.3.5. Recent Initiatives (2017-2019)
11.4. Eisai Co. Ltd.
11.4.1. Company Snapshot
11.4.2. Company Overview
11.4.3. Financial Performance (2015-2019)
11.4.3.1. Net Revenue
11.4.3.2. Gross Profit
11.4.3.3. Geographical Revenue, 2019
11.4.4. Product Offerings
11.4.5. Recent Initiatives (2017-2019)
11.5. Lundbeck A/S
11.5.1. Company Snapshot
11.5.2. Company Overview
11.5.3. Financial Performance (2015-2019)
11.5.3.1. Net Revenue
11.5.3.2. Gross Profit
11.5.3.3. Geographical Revenue, 2019
11.5.4. Product Offerings
11.5.5. Recent Initiatives (2017-2019)
11.6. Teva Pharmaceuticals Industries Ltd.
11.6.1. Company Snapshot
11.6.2. Company Overview
11.6.3. Financial Performance (2015-2019)
11.6.3.1. Net Revenue
11.6.3.2. Gross Profit
11.6.3.3. Geographical Revenue, 2019
11.6.4. Product Offerings
11.6.5. Recent Initiatives (2017-2019)
11.7. Eli Lilly and Company
11.7.1. Company Snapshot
11.7.2. Company Overview
11.7.3. Financial Performance (2015-2019)
11.7.3.1. Net Revenue
11.7.3.2. Gross Profit
11.7.3.3. Geographical Revenue, 2019
11.7.4. Product Offerings
11.7.5. Recent Initiatives (2017-2019)
11.8. TauRx Pharmaceuticals Ltd
11.8.1. Company Snapshot
11.8.2. Company Overview
11.8.3. Financial Performance (2015-2019)
11.8.3.1. Net Revenue
11.8.3.2. Gross Profit
11.8.3.3. Geographical Revenue, 2019
11.8.4. Product Offerings
11.8.5. Recent Initiatives (2017-2019)
11.9. VTV THERAPEUTICS
11.9.1. Company Snapshot
11.9.2. Company Overview
11.9.3. Financial Performance (2015-2019)
11.9.3.1. Net Revenue
11.9.3.2. Gross Profit
11.9.3.3. Geographical Revenue, 2019
11.9.4. Product Offerings
11.9.5. Recent Initiatives (2017-2019)
11.10. Hoffman-La Roche Ltd.
11.10.1. Company Snapshot
11.10.2. Company Overview
11.10.3. Financial Performance (2015-2019)
11.10.3.1. Net Revenue
11.10.3.2. Gross Profit
11.10.3.3. Geographical Revenue, 2019
11.10.4. Product Offerings
11.10.5. Recent Initiatives (2017-2019)
11.11. Other Notable Players
12. Conclusion
13. Glossary
Associated Visiongain Reports
Visiongain Report Sales Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1 Alzheimer’s Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2 Alzheimer’s Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3 Alzheimer’s Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4 Alzheimer’s Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5 Alzheimer’s Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6 Alzheimer’s Drugs Market Drivers & Restraints 2020
Table 7 Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 8 Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 9 Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 10 Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 11 Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 12 Donepezil Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13 Donepezil Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14 Donepezil Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15 Donepezil Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16 Donepezil Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17 Rivastigmine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 18 Rivastigmine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 19 Rivastigmine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 20 Rivastigmine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 21 Galantamine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 22 Galantamine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 23 Galantamine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 24 Galantamine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 25 Galantamine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 26 Memantine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 27 Memantine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 28 Memantine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 29 Memantine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 30 Memantine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 31 Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 32 Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 33 Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 34 Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 35 Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 36 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 37 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 38 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 39 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 40 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 41 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 42 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 43 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 44 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 45 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 46 E-Commerce Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 47 E-Commerce Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 48 E-Commerce Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 49 E-Commerce Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 50 E-Commerce Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 51 Regional Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 52 Regional Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 53 Regional Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 54 Regional Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 55 Regional Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 56 North America Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 57 North America Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 58 North America Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 59 North America Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 60 North America Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 61 North America Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 62 North America Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 63 North America Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 64 North America Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 65 North America Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 66 North America Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 67 North America Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 68 North America Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 69 North America Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 70 North America Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 71 US Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 72 US Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 73 US Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 74 US Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 75 US Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 76 Canada Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 77 Canada Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 78 Canada Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 79 Canada Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 80 Canada Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 81 Europe Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 82 Europe Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 83 Europe Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 84 Europe Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 85 Europe Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 86 Europe Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 87 Europe Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 88 Europe Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 89 Europe Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 90 Europe Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 91 Europe Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 92 Europe Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 93 Europe Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 94 Europe Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 95 Europe Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 96 UK Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 97 UK Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 98 UK Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 99 UK Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 100 UK Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 101 Germany Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 102 Germany Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 103 Germany Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 104 Germany Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 105 Germany Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 106 France Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 107 France Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 108 France Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 109 France Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 110 France Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 111 Rest of Europe Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 112 Rest of Europe Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 113 Rest of Europe Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 114 Rest of Europe Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 115 Rest of Europe Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 116 Asia Pacific Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 117 Asia Pacific Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 118 Asia Pacific Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 119 Asia Pacific Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 120 Asia Pacific Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 121 Asia Pacific Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 122 Asia Pacific Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 123 Asia Pacific Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 124 Asia Pacific Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 125 Asia Pacific Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 126 Asia Pacific Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 127 Asia Pacific Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 128 Asia Pacific Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 129 Asia Pacific Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 130 Asia Pacific Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 131 China Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 132 China Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 133 China Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 134 China Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 135 China Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 136 India Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 137 India Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 138 India Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 139 India Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 140 India Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 141 Japan Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 142 Japan Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 143 Japan Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 144 Japan Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 145 Japan Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 146 RoAPAC Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 147 RoAPAC Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 148 RoAPAC Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 149 RoAPAC Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 150 RoAPAC Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 151 Middle East Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 152 Middle East Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 153 Middle East Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 154 Middle East Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 155 Middle East Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 156 Middle East Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 157 Middle East Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 158 Middle East Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 159 Middle East Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 160 Middle East Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 161 Latin America Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 162 Latin America Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 163 Latin America Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 164 Latin America Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 165 Latin America Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 166 Latin America Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 167 Latin America Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 168 Latin America Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 169 Latin America Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 170 Latin America Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 171 Africa Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 172 Africa Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 173 Africa Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 174 Africa Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 175 Africa Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 176 Africa Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 177 Africa Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 178 Africa Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 179 Africa Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 180 Africa Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 181 Leading 10 Alzheimer’s Drugs Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 182 Pfizer, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 183 Pfizer, Inc. Alzheimer’s Drugs Selected Recent Contracts 2019 (Date, Contract Treatment Type, Details)
Table 184 Pfizer, Inc. Alzheimer’s Drugs Product Offering (Segment, Product Offerings)
Table 185 Janssen Pharmaceutical Profile 2019 (CEO, HQ, Founded, Website)
Table 186 Janssen Pharmaceutical Alzheimer’s Drugs Selected Recent Contracts 2019 (Date, Contract Treatment Type, Details)
Table 187 Janssen Pharmaceutical Alzheimer’s Drugs Product Offering (Segment, Product Offerings)
Table 188 Novartis International AG Profile 2019 (CEO, HQ, Founded, Website)
Table 189 Novartis International AG Alzheimer’s Drugs Selected Recent Contracts 2017-2019 (Date, Contract Treatment Type, Details)
Table 190 Novartis International AG Alzheimer’s Drugs Product Offering (Segment, Product Offerings)
Table 191 Eisai Co. Ltd. Profile 2019 (CEO, HQ, Founded, Website)
Table 192 Eisai Co. Ltd. Alzheimer’s Drugs Selected Recent Contracts 2015-2019 (Date, Contract Treatment Type, Details)
Table 193 Eisai Co. Ltd. Alzheimer’s Drugs Product Offering (Segment, Product Offerings)
Table 194 Lundbeck A/S Profile 2019 (CEO, HQ, Founded, Website)
Table 195 Lundbeck A/S Alzheimer’s Drugs Selected Recent Contracts 2015-2019 (Date, Contract Treatment Type, Details)
Table 196 Lundbeck A/S Alzheimer’s Drugs Product Offering (Segment, Product Offerings)
Table 197 Teva Pharmaceuticals Industries Ltd. Profile 2019 (CEO, HQ, Founded, Website)
Table 198 Teva Pharmaceuticals Industries Ltd. Alzheimer’s Drugs Selected Recent Contracts 2015-2019 (Date, Contract Treatment Type, Details)
Table 199 Teva Pharmaceuticals Industries Ltd. Alzheimer’s Drugs Product Offering (Segment, Product Offerings)
Table 200 Eli Lilly and Company Profile 2019 (CEO, HQ, Founded, Website)
Table 201 Eli Lilly and Company Alzheimer’s Drugs Selected Recent Contracts 2015-2019 (Date, Contract Treatment Type, Details)
Table 202 Eli Lilly and Company Alzheimer’s Drugs Product Offering (Segment, Product Offerings)
Table 203 TauRx Pharmaceuticals Ltd Profile 2019 (CEO, HQ, Founded, Website)
Table 204 TauRx Pharmaceuticals Ltd Alzheimer’s Drugs Selected Recent Contracts 2015-2019 (Date, Contract Treatment Type, Details)
Table 205 TauRx Pharmaceuticals Ltd Alzheimer’s Drugs Product Offering (Segment, Product Offerings)
Table 206 VTV THERAPEUTICS Profile 2019 (CEO, HQ, Founded, Website)
Table 207 VTV THERAPEUTICS Alzheimer’s Drugs Selected Recent Contracts 2015-2019 (Date, Contract Treatment Type, Details)
Table 208 VTV THERAPEUTICS Alzheimer’s Drugs Product Offering (Segment, Product Offerings)
Table 209 Hoffman-La Roche Ltd. Profile 2019 (CEO, HQ, Founded, Website)
Table 210 Hoffman-La Roche Ltd. Alzheimer’s Drugs Selected Recent Contracts 2015-2019 (Date, Contract Treatment Type, Details)
Table 211 Hoffman-La Roche Ltd. Alzheimer’s Drugs Product Offering (Segment, Product Offerings)
Table 212 Other Companies Involved in the Alzheimer’s Drugs Market 2020 (Company, Location)
LIST OF FIGURES
Figure 1 Alzheimer’s Drugs Market By Drugs Overview
Figure 2 Alzheimer’s Drugs Market By Distribution Channel Overview
Figure 3 Alzheimer’s Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 4 Alzheimer’s Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 5 Alzheimer’s Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 6 Alzheimer’s Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 7 Alzheimer’s Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 8 Alzheimer’s Drugs Market Drivers & Restraints 2020
Figure 9 Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 10 Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 11 Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 12 Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 13 Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 14 Donepezil Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 15 Donepezil Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 16 Donepezil Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 17 Donepezil Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 18 Donepezil Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 19 Rivastigmine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 20 Rivastigmine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 21 Rivastigmine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 22 Rivastigmine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 23 Galantamine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 24 Galantamine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 25 Galantamine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 26 Galantamine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 27 Galantamine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 28 Memantine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 29 Memantine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 30 Memantine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 31 Memantine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 32 Memantine Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 33 Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 34 Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 35 Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 36 Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 37 Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 38 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 39 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 40 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 41 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 42 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 43 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 44 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 45 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 46 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 47 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 48 E-Commerce Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 49 E-Commerce Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 50 E-Commerce Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 51 E-Commerce Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 52 E-Commerce Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 53 Regional Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 54 Regional Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 55 Regional Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 56 Regional Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 57 Regional Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 58 North America Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 59 North America Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 60 North America Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 61 North America Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 62 North America Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 63 North America Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 64 North America Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 65 North America Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 66 North America Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 67 North America Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 68 North America Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 69 North America Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 70 North America Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 71 North America Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 72 North America Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 73 US Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 74 US Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 75 US Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 76 US Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 77 US Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 78 Canada Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 79 Canada Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 80 Canada Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 81 Canada Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 82 Canada Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 83 Europe Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 84 Europe Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 85 Europe Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 86 Europe Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 87 Europe Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 88 Europe Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 89 Europe Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 90 Europe Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 91 Europe Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 92 Europe Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 93 Europe Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 94 Europe Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 95 Europe Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 96 Europe Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 97 Europe Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 98 UK Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 99 UK Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 100 UK Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 101 UK Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 102 UK Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 103 Germany Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 104 Germany Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 105 Germany Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 106 Germany Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 107 Germany Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 108 France Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 109 France Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 110 France Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 111 France Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 112 France Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 113 Rest of Europe Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 114 Rest of Europe Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 115 Rest of Europe Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 116 Rest of Europe Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 117 Rest of Europe Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 118 Asia Pacific Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 119 Asia Pacific Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 120 Asia Pacific Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 121 Asia Pacific Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 122 Asia Pacific Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 123 Asia Pacific Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 124 Asia Pacific Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 125 Asia Pacific Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 126 Asia Pacific Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 127 Asia Pacific Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 128 Asia Pacific Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 129 Asia Pacific Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 130 Asia Pacific Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 131 Asia Pacific Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 132 Asia Pacific Alzheimer’s Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 133 China Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 134 China Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 135 China Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 136 China Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 137 China Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 138 India Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 139 India Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 140 India Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 141 India Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 142 India Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 143 Japan Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 144 Japan Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 145 Japan Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 146 Japan Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 147 Japan Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 148 RoAPAC Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 149 RoAPAC Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 150 RoAPAC Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 151 RoAPAC Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 152 RoAPAC Alzheimer’s Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 153 Middle East Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 154 Middle East Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 155 Middle East Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 156 Middle East Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 157 Middle East Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 158 Middle East Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 159 Middle East Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 160 Middle East Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 161 Middle East Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 162 Middle East Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 163 Latin America Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 164 Latin America Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 165 Latin America Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 166 Latin America Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 167 Latin America Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 168 Latin America Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 169 Latin America Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 170 Latin America Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 171 Latin America Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 172 Latin America Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 173 Africa Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 174 Africa Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 175 Africa Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 176 Africa Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 177 Africa Alzheimer’s Drugs Market Forecast by Drugs 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 178 Africa Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 179 Africa Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 180 Africa Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 181 Africa Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 182 Africa Alzheimer’s Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Companies Profiled in the Report
1. Pfizer, Inc.
2. Janssen Pharmaceutical
3. Novartis International AG
4. Eisai Co. Ltd., Lundbeck A/S
5. Teva Pharmaceuticals Industries Ltd.
6. Eli Lilly and Company
7. TauRx Pharmaceuticals Ltd
8. VTV Therapeutics
9. Hoffman-La Roche Ltd.
10. AstraZeneca plc
11. AC Immune.
List of Companies Mentioned in the Report:
1. Shionogi & Co.
2. Shanghai Fosun Pharmaceutical
3. Stada Arzneimittel
4. Lundbeck
5. Zhejiang International
6. Lupin
7. Taisho Pharmaceutical
8. Tasly Pharmaceutical
9. Ipsen
10. Sino Biopharmaceutical
11. Ono Pharmaceutical
12. Aurobindo
13. Cipla
14. Johnson & Johnson
15. Roche
16. Novartis
17. Sanofi
18. Bayer
19. Merck & Co. (MSD)
20. Eli Lilly
21. Astrazeneca
22. Teva
23. CR Pharmaceutical
24. Bristol-Myers Squibb
25. Merck (KGaA)
26. Novo Nordisk
27. Takeda
28. Allergan
29. Astellas Pharma
30. Mylan
31. Otsuka
32. Daiichi Sankyo
33. Valeant Pharmaceuticals
34. UCB
35. Zoetis
36. Eisai
37. Chugai Pharmaceutical
38. Perrigo
39. Sun Pharmaceutical
40. Mitsubishi Tanabe Pharma
41. Sichuan Languang Development
42. Sumitomo Dainippon Pharma
43. Yunnan Baiyao
44. Aspen Pharmacare
45. Endo
46. Kangmei Pharmaceutical
47. Galenica
48. Guangzhou Baiyunshan Pharmaceutical
49. Kyowa Hakko Kirin
50. Mallinckrod
List of Organizations Mentioned in the Report:
1. European Commission
2. European Medicines Agency
3. Food and Drug Administration
4. Medicines and Healthcare Regulatory Agency
5. Ministry of Industry and Information technology
6. National Institute of Health
7. World Health Organisation (WHO)
8. Centers for Disease Control and Prevention
9. National Academy of Medicine
10. Agency for Healthcare Research and Quality
11. National Accreditation Board for Hospitals & Healthcare Providers
12. National Institute for Health Research
13. Chinese Food and Drug Administration
14. Care Quality Commission
15. British Medical Association
16. United States Department of Health and Human Services
17. Healthcare Information and Management Systems Society
18. Patient safety organization
19. NHS Digital
20. Australian Commission On Safety And Quality In Health Care
1. Pfizer, Inc.
2. Janssen Pharmaceutical
3. Novartis International AG
4. Eisai Co. Ltd., Lundbeck A/S
5. Teva Pharmaceuticals Industries Ltd.
6. Eli Lilly and Company
7. TauRx Pharmaceuticals Ltd
8. VTV Therapeutics
9. Hoffman-La Roche Ltd.
10. AstraZeneca plc
11. AC Immune.
List of Companies Mentioned in the Report:
1. Shionogi & Co.
2. Shanghai Fosun Pharmaceutical
3. Stada Arzneimittel
4. Lundbeck
5. Zhejiang International
6. Lupin
7. Taisho Pharmaceutical
8. Tasly Pharmaceutical
9. Ipsen
10. Sino Biopharmaceutical
11. Ono Pharmaceutical
12. Aurobindo
13. Cipla
14. Johnson & Johnson
15. Roche
16. Novartis
17. Sanofi
18. Bayer
19. Merck & Co. (MSD)
20. Eli Lilly
21. Astrazeneca
22. Teva
23. CR Pharmaceutical
24. Bristol-Myers Squibb
25. Merck (KGaA)
26. Novo Nordisk
27. Takeda
28. Allergan
29. Astellas Pharma
30. Mylan
31. Otsuka
32. Daiichi Sankyo
33. Valeant Pharmaceuticals
34. UCB
35. Zoetis
36. Eisai
37. Chugai Pharmaceutical
38. Perrigo
39. Sun Pharmaceutical
40. Mitsubishi Tanabe Pharma
41. Sichuan Languang Development
42. Sumitomo Dainippon Pharma
43. Yunnan Baiyao
44. Aspen Pharmacare
45. Endo
46. Kangmei Pharmaceutical
47. Galenica
48. Guangzhou Baiyunshan Pharmaceutical
49. Kyowa Hakko Kirin
50. Mallinckrod
List of Organizations Mentioned in the Report:
1. European Commission
2. European Medicines Agency
3. Food and Drug Administration
4. Medicines and Healthcare Regulatory Agency
5. Ministry of Industry and Information technology
6. National Institute of Health
7. World Health Organisation (WHO)
8. Centers for Disease Control and Prevention
9. National Academy of Medicine
10. Agency for Healthcare Research and Quality
11. National Accreditation Board for Hospitals & Healthcare Providers
12. National Institute for Health Research
13. Chinese Food and Drug Administration
14. Care Quality Commission
15. British Medical Association
16. United States Department of Health and Human Services
17. Healthcare Information and Management Systems Society
18. Patient safety organization
19. NHS Digital
20. Australian Commission On Safety And Quality In Health Care
Download sample pages
Complete the form below to download your free sample pages for Alzheimer’s Drugs Market Report to 2031Download sample pages
Complete the form below to download your free sample pages for Alzheimer’s Drugs Market Report to 2031Do you have any custom requirements we can help you with?
Any specific country, geo region, market segment or specific company information?
Email us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
Would you like a free report overview of the report of your choice?
If so, please drop an email to Sara Peerun stating your chosen report title to sara.peerun@visiongain.com
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.”
Dr Luz Chapa Azuella, Mexico
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia
Visiongain Pharma
Visiongain Pharma
Visiongain PharmaLatest Pharma news
Visiongain Publishes Vaccine Contract Manufacturing Market Report 2023-2033
The global Vaccine Contract Manufacturing Market is projected to grow at a CAGR of 13.2% by 2033
24 May 2023
Visiongain Publishes Cell & Gene Therapy Cold Chain Logistics Market Report 2023-2033
The global Cell & Gene Therapy Cold Chain Logistics market is projected to grow at a CAGR of 15% by 2033
23 May 2023
Visiongain Publishes Single-use Bioprocessing Probes & Sensors Market Report 2023-2033
The global Single-Use Bioprocessing Probes & Sensors market was valued US$2,493.8 million in 2022 and is projected to grow at a CAGR of 15.2% during the forecast period 2023-2033.
22 May 2023
Visiongain Publishes Dental Consumables Market Report 2023-2033
The global Dental Consumables market is valued at US$21,759.4 million in 2023 and is expected to register a CAGR of 8% from 2023 to 2033.
22 May 2023
